Mycobacterium tuberculosis PptT Inhibitors Based on Heterocyclic Replacements of Amidinoureas.

TitleMycobacterium tuberculosis PptT Inhibitors Based on Heterocyclic Replacements of Amidinoureas.
Publication TypeJournal Article
Year of Publication2023
AuthorsOttavi S, Li K, Cacioppo JG, Perkowski AJ, Ramesh R, Gold BS, Ling Y, Roberts J, Singh A, Zhang D, Mosior J, Goullieux L, Roubert C, Bacqué E, Sacchettini JC, Nathan CF, Aubé J
JournalACS Med Chem Lett
Volume14
Issue7
Pagination970-976
Date Published2023 Jul 13
ISSN1948-5875
Abstract

4'-Phosphopantetheinyl transferase (PptT) is an essential enzyme for Mycobacterium tuberculosis (Mtb) survival and virulence and therefore an attractive target for a tuberculosis therapeutic. In this work, two modeling-informed approaches toward the isosteric replacement of the amidinourea moiety present in the previously reported PptT inhibitor AU 8918 are reported. Although a designed 3,5-diamino imidazole unexpectedly adopted an undesired tautomeric form and was inactive, replacement of the amidinourea moiety afforded a series of active PptT inhibitors containing 2,6-diaminopyridine scaffolds.

DOI10.1021/acsmedchemlett.3c00162
Alternate JournalACS Med Chem Lett
PubMed ID37465309
PubMed Central IDPMC10351052
Grant ListU19 AI111143 / AI / NIAID NIH HHS / United States
P01 AI095208 / AI / NIAID NIH HHS / United States
P50 GM069663 / GM / NIGMS NIH HHS / United States
R01 AI155510 / AI / NIAID NIH HHS / United States
P30 CA016086 / CA / NCI NIH HHS / United States

Weill Cornell Medicine Microbiology and Immunology 1300 York Avenue, Box 62 New York, NY 10065 Phone: (212) 746-6505 Fax: (212) 746-8587